



ASX ANNOUNCEMENT

4 August 2023

Cleansing Statement

[CardieX Limited](#) (ASX: **CDX**) (**CardieX**, the **Company**) advises that on 4 August 2023, it issued a total of 218,003 Fully Paid Ordinary Shares without disclosure to the recipient under Part 6D.2 of the Corporations Act 2001 (Cth) (the **Corporations Act**).

The Company hereby gives notice under Section 708A(5) of the Corporations Act, and for all other purposes, that:

- (a) the company has issued the Securities without disclosure to the recipient under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, the Company has complied with the provisions of:
 - a. Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
- (c) As at the date of this notice there is no information:
 - a. That has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. That investors and their professional advisers would reasonably require for the purpose of making an information assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
 - ii. the rights and liabilities attaching to the relevant securities.

to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

**Media Relations**

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger

Managing Director, Integrous Communications

mselinger@integcom.com

About CardieX

CardieX is a medical technology company focused on developing vascular biomarkers. Its ATCOR subsidiary is a leader in medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders based on the Company's SphygmoCor® central blood pressure technology. CardieX's CONNEQT subsidiary develops and markets medical devices, digital solutions, and wearables, for home health, decentralized clinical trials, and remote patient monitoring. CardieX is listed on the Australian Stock Exchange (ASX:CDX).